New studies link pregnancy infections to autism and show potential skin healing drug
最新研究將懷孕期間的感染與自閉症聯繫起來，並展示了一種潛在的皮膚癒合藥物
更新於: 2026年9月24日 上午03:30
Recent scientific breakthroughs are bridging the gap between immunology and neurology, offering new insights into autism spectrum disorder (ASD).
最近的科學突破正填補免疫學與神經學之間的鴻溝，為自閉症類群障礙症 (ASD) 提供了新見解。
Researchers are focusing on Maternal Immune Activation, where infections during pregnancy trigger an immune response.
研究人員正聚焦於「母體免疫活化」(Maternal Immune Activation)，即懷孕期間的感染觸發免疫反應。
This release of pro-inflammatory proteins, specifically Interleukin-17a (IL-17a), can cross the placental barrier and influence fetal brain development.
這種促發炎蛋白質的釋放，特別是介白素-17a (IL-17a)，能穿過胎盤屏障並影響胎兒大腦發育。
Interestingly, high levels of IL-17a are also linked to chronic skin conditions like psoriasis.
有趣的是，高濃度的 IL-17a 也與慢性皮膚病如乾癬有關。
This connection has led scientists to explore whether existing dermatological drugs, which inhibit IL-17a, might help treat certain autism-related symptoms.
這種連結促使科學家探索，現有的、能抑制 IL-17a 的皮膚科藥物，是否能協助治療某些與自閉症相關的症狀。
Early studies using animal models have shown promise in reducing social and behavioral challenges.
早期的動物模型研究已顯示其在減輕社交與行為挑戰方面的潛力。
However, experts urge caution; while these findings are encouraging, ASD is a highly complex, heterogeneous condition with various genetic and environmental influences.
然而，專家呼籲應謹慎以對；雖然這些發現令人振奮，但 ASD 是一種極其複雜且異質性極高的疾病，受到多種遺傳與環境因素影響。
The research does not suggest a cure, but it represents a shift toward precision medicine, where scientists aim to target specific biological pathways rather than just managing symptoms.
這項研究並非宣稱能治癒，但它代表了向精準醫療邁進的一步，科學家旨在針對特定的生物途徑而非僅僅管理症狀。
As investigators continue to study the systemic roots of brain development, this intersection of immunology and neurology remains one of the most exciting areas of modern medical research.
隨著研究人員持續探索大腦發育的系統性根源，免疫學與神經學的交匯處仍是現代醫學研究中最令人興奮的領域之一。
